SGLT2 and GLP1 were prescribed in 39% and 8% of patients at 1-year, respectively. Likelihood of having an active SGLT2 prescription at 1-year was higher for patients prescribed it at discharge compared to those who were not (RR 2.6; 95% CI 1.9-3.4). Likelihood of having an active ...
Cardiorenal and mortality benefits reported for SGLT2i and GLP-1 RA.aSGLT2i. CVOTs for empagliflozin, canagliflozin, dapagliflozin and ertugliflozin have all pointed to beneficial effects on HHF and renal function outcomes [2,3,4,5,7,11,13], either in a population with T2D and established C...
Advancements in glucose-lowering medications have transformed T2D management, with SGLT2 inhibitors and GLP-1 RAs proven to benefit cardiovascular and kidney outcomes.2These data, however, have not yet confirmed this treatment effect by individual characteristics, including age and sex, with Hanlon and...
Cardiorenal and mortality benefits reported for SGLT2i and GLP-1 RA.aSGLT2i. CVOTs for empagliflozin, canagliflozin, dapagliflozin and ertugliflozin have all pointed to beneficial effects on HHF and renal function outcomes [2,3,4,5,7,11,13], either in a population with T2D and established C...
Individuals were included if they had initiated one or more of the following four second- line glucose-lowering medications: SGLT2is, GLP1-RAs, dipeptidyl peptidase-4 inhibitors (DPP4is) or sulfonylureas (SUs). Treatment initiation was defined as a filled prescrip- tion for a study medication ...
From glucagon-like peptide-1s (GLP-1s) to non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), there are multiple variations of medications suited to treat chronic kidney disease (CKD). However, when it comes to the beginning of a CKD medication regimen, experts believe sodium-glucose ...
Sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 receptor (GLP-1-R) agonists are novel therapeutic agents used for the management of type 2 diabetes mellitus (T2DM). Recently, large-scale randomized clinical trials have been conducted to assess the cardiovascular safety...
Newer classes of glucose-lowering agents (GLAs), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is), have been shown to improve liver-related biomarkers. However, their effects on the development of NAFLD/NASH remain inconclusive....
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms Ronald M. Goldenberg, Jeremy D. Gilbert, Robyn L. Houlden, Tayyab S. Khan, Sapna Makhija, C. David Mazer, show all Pages ...
(DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors. Whereas a variety of conventional antidiabetic drugs have been shown to retard the progression of nephropathy through glycemic control [1], there are a limited number of ...